50 results about "Atropine" patented technology

The invention belongs to the field of pharmaceutical preparations, and particularly relates to an atropine pharmaceutical composition which contains pharmaceutically acceptable salt of atropine, sulfonic cation exchange resin and a suspending aid, and the suspending aid is selected from one or more of carbomer, povidone and hydroxyethyl cellulose. According to the atropine pharmaceutical composition formula, the content of free atropine in liquid medicine can be obviously reduced, so that the content of related substances can be controlled within a lower range, and the medicine has better stability under the room temperature condition and has a better medicine release effect.

The present application provides compositions, methods, and dispensers for topical delivery of ophthalmological active pharmaceutical ingredients (APIs). In one example, a composition is provided comprising an active pharmaceutical ingredient soluble in MCT wherein the API is not atropine or a salt thereof; a medium chain triglyceride (MCT); and a semi-fluorinated alkane compound. In another example, a nano-emulsion is provided comprising about an active pharmaceutical ingredient soluble in MCT; a medium chain triglyceride (MCT); and a semi-fluorinated alkane compound, wherein the nano-emulsion has a droplet particle size D90 of less than about 100 nm. Dispensers containing the compositions are also provided and include glass and polyethylene terephthalate dispensers or containers. Methods of using the compositions are also provided and include a method for treating an ocular condition in a subject comprising administering the compositions or nano-emulsions to an eye of the subject. The present application also provides compositions and methods for treating ophthalmological conditions such as presbyopia and glaucoma. The compositions can comprise a muscarinic cholinergic receptor agonist and a semi-fluorinated alkane compound; or can comprise a muscarinic cholinergic receptor agonist, a semi-fluorinated alkane compound, and an organic cosolvent. The compositions can confer chemical stability of the muscarinic cholinergic receptor agonist.

The invention discloses an application of CHRM3 gene polymorphism in diagnosis or screening of atropine susceptible myopia crowds, and finds that an SNP site rs60234066 is related to diagnosis of the atropine susceptible myopia crowds for the first time, and whether a tested crowd is the atropine susceptible myopia crowd or not is judged by detecting an SNP genotype. The SNP site rs60234066 has relatively high accuracy in diagnosis of atropine susceptible myopia people, can be used for early diagnosis or screening of the atropine susceptible myopia people to improve the early intervention rate of related disease people, so that the clinical guidance effect of the related disease people is improved, the myopia progress is reduced, and the SNP site rs60234066 has a wide clinical application prospect.

Provided is a method for producing a solution of atropine with improved recovery. A method for producing a solution of atropine-211, comprising the steps of: irradiating bismuth with alpha rays, generating atropine-211 in the bismuth, and distilling the bismuth irradiated with the alpha rays, separating and purifying atropine-211, and dissolving it in an aqueous sodium bicarbonate solution.

Methods of preventing or delaying the onset of myopia in a pre-myopia patient and of reducing or preventing the progression of myopia in a low-myopia patient by using a composition comprising less than 0.025% atropine are disclosed.

The invention pertains to a new formulation of atropine in the form of a gel, in particular for use for the treatment of treatment of sialorrhea.

The present invention provides a low-concentration atropine nanoemulsion, its preparation method and application, belonging to the field of pharmaceutical technology. In the present invention, atropine is used as the main drug, and oil and surfactant are successfully used to encapsulate atropine in the oil phase, solving the problem of poor stability of atropine aqueous solution, realizing the slow release of atropine in the eye, improving the bioavailability of the drug, reducing adverse reactions such as mydriasis, photophobia, and dry eye, having good biocompatibility, and overcoming the problem of irritation to the eye caused by too high local concentration of ordinary eye drops. The nanoemulsion and lower-concentration nanoemulsion of the present invention have high bioavailability, have the effect of effectively delaying the development of myopia, have high safety, small side effects, and good application prospects.

The invention discloses an atropine derivative and a preparation method and application thereof, and belongs to the technical field of medical preparations, the atropine derivative and a salt or a pharmaceutical composition thereof can be used as a ciliary muscle paralysis agent and / or a mydriasis agent; the choroid and sclera functions can be regulated and controlled by improving choroid microcirculation and sclera hypoxia environment, inhibiting an HIF-1alpha signal channel and directly targeting sclera fibroblasts to inhibit extracellular matrix generation and remodeling; the medicine is used for relieving muscae volitantes symptoms; amblyopia, lazy eye diseases or myopia can be relieved; for treating or preventing myopia; the traditional Chinese medicine composition has good maintenance time and treatment effect, can obviously reduce the use frequency and use amount, improves the use experience, and reduces the medicine use cost.

A method of converting a protected pyrrole into a tetrachlorobicyclic compound. The tetrachlorobicyclic compound may include benzyl 2.2.4.4-tetrachloro-3-oxo-8-azabicyclo[3.2.1]oct-6-ene-8-carboxylate.

The invention provides a composition capable of ventilating, relieving abdominal distension and pain and improving constipation and application, and relates to the technical field of medicines. The composition is prepared from the following components: 30-40 parts of hawthorn, 5-15 parts of malt, 1-5 parts of Chinese yam, 2-10 parts of endothelium corneum gigeriae galli, 5-15 parts of orange peel and 3-10 parts of semen raphani. All the components supplement each other and are indispensable, so that the synergistic effects of ventilating, relieving abdominal distension and pain and improving constipation are achieved. The composition disclosed by the invention has the remarkable effects of ventilating, relieving abdominal distension and pain and improving the gastric emptying rate and the small intestine propulsion rate on postoperative enteroparalysis rats, atropine-induced gastrointestinal dysfunction rats and iodoacetamide intragastric lavage and small platform combined gastrointestinal dysfunction rats; for constipation mice, the traditional Chinese medicine composition has the functions of remarkably reducing the first-grain black defecation time, increasing the defecation grain number and weight, increasing the content of 5-HT and SP in the bodies of the constipation mice, reducing the content of VIP and improving intestines and stomach.

The invention relates to an application of atropine (Atropine, C17H23NO3) in preparation of a medicine for treating sleep disorder. Existing sleep drugs are generally ineffective to sleep disorders related to circadian rhythm and cannot restore a normal sleep-awakening period for many patients, and benzodiazepine and non-benzodiazepine hypnotics have significant side effects such as dependency, cognitive disorder and dizziness, and long-term use of the drugs is limited. According to the invention, a per3 gene defect zebrafish model is used for drug screening, and a new application of a clinically used drug, namely atropine, in preparation of drugs for treating sleep disorders is provided for the first time, especially for treating sleep disorders which are insensitive to existing sedative drugs or are related to circadian rhythm disorder, and particularly for treating sleep disorders which are not sensitive to existing sedative drugs or are related to circadian rhythm disorder, circadian rhythm disorder, circadian rhythm disorder and circadian rhythm disorder. The optimal curative effect can be achieved in the indication by 12 mu M, the sleep-awakening cycle disorder caused by Per3 defects is improved, and the normal sleep-awakening cycle is recovered.

The invention relates to fast-acting, multi-layered, orally disintegrating, and film-shaped pharmaceutical formulations containing anesthetic drugs (midazolam, ketamine, atropine, or a combination thereof) used to provide sedation in children prior to surgical operations or interventions, and the production method of these formulations.

The invention belongs to the technical field of medicine. The invention relates to the field of eye drops, in particular to application of ipratropium bromide in the aspect of preventing or improving myopia and eye drops containing ipratropium bromide. The research proves that the single drug of the ipratropium bromide can effectively inhibit the growth of the ocular axis and the deterioration of the diopter, and the brand new medicinal value of the ipratropium bromide in the aspect of preventing and improving the myopia is disclosed for the first time. More importantly, the invention finds that the combination of the ipratropium bromide and the diquafosol sodium can generate a remarkable synergistic effect, and the curative effect of the combined preparation is far better than that of a single drug and even better than that of a clinical drug atropine. The invention provides a safe, effective and long-term brand new drug choice for myopia prevention and control, and has good application prospect and value.

An eye drop composition for the prevention or treatment of ophthalmic diseases is provided, including: (a) a lyophilized preparation including atropine or a pharmaceutically acceptable salt thereof; and (b) a reconstituting diluent, the lyophilized preparation being separate from the reconstituting diluent. A method for preparing the eye drop composition is also provided, which includes steps of: (a) contacting a buffer salt system in the lyophilized preparation with the atropine or the pharmaceutically acceptable salt thereof, and optionally, one or more of a matrix agent and a stabilizer, and lyophilizing to obtain the lyophilized preparation; and (b) contacting a buffer salt system in the reconstitution diluent optionally with one or more of an osmotic pressure regulator, a chelating agent, and a bacteriostatic agent to obtain the reconstitution diluent.

In one general aspect, the present disclosure provides fatty acid esters of atropine, or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprising these esters is also provided. In one example, the composition comprises a semifluorinated alkane vehicle, such as perfluorohexyloctane (F6H8). Method of using the fatty esters of atropine include medical fields where atropine is known to be useful. In one example, the disclosure provides methods of using the compound as cycloplegic agent and / or as mydriatic.

The utility model discloses an out-of-focus and dot matrix composite lens for early-stage myopia prevention, which comprises a lens main body, a correction area, a central optical correction area, an out-of-focus prevention and control area and a dot matrix area, and the central optical correction area adopts a positive spherical lens. Compared with the prior art, the pair of glasses has the advantages that 1, a small number of positive spherical lenses are additionally arranged in the central optical area of the main lens, teenagers with insufficient hyperopia reserve are compensated, and the development speed of an eye axis is intervened, so that the effect of delaying the occurrence and development of myopia in the early stage of myopia is realized; 2, the safety is better than that of medicine relaxation, no side effect exists, mydriasis medicine atropine is replaced by optical relaxation, no side effect exists, the safety is higher, hyperopia out-of-focus and focusing pressure can be reduced when the eyes see far and near, and the eyes are easier to use; and 3, a dot matrix area is added in the out-of-focus gap, so that the contrast sensitivity can be further reduced, the stimulation of a high-contrast visual signal to retina cone cells is reduced, and the effect of preventing myopia is improved.

The invention discloses an atropine myopia prevention and control evidence-based dialogue method and system, and belongs to the technical field of prevention and control data intelligence. The method comprises the steps of question analysis: performing semantic analysis on a received user question; retrieval of evidence-based evidences: performing retrieval enhancement according to a semantic analysis result, and obtaining the evidence-based evidences and sources and levels of the evidence-based evidences from the atropine myopia prevention and control knowledge graph; inference chain generation: combining evidence-based evidences with cues, and guiding the model to generate inference chain content according to the steps of individual core feature analysis, atropine prevention and control scheme matching, safety evaluation and scheme optimization through a thinking chain CoT; and answer generation: according to the evidence-based evidence and the reasoning chain content, generating different types of atropine myopia prevention and control answers. According to the method and the device, the matching between each core entity in the output atropine myopia prevention and control scheme and individual requirements is improved, and the accuracy of the atropine myopia prevention and control scheme is improved.

The invention discloses a 5-fluorouracil atropine double-drug sustained release preparation based on temperature-sensitive hydrogel as well as a preparation method and application of the 5-fluorouracil atropine double-drug sustained release preparation. The double-drug sustained release preparation is prepared from the following raw materials: a vagus nerve blocking agent, 5-fluorouracil (5-FU) and temperature-sensitive hydrogel (PLEL), wherein the vagus nerve blocking agent comprises atropine. According to the invention, the chemotherapeutic drug 5-FU and the vagus nerve signal blocking agent (such as atropine) are co-delivered through the temperature-sensitive hydrogel for the first time to realize'double strike 'on gastric cancer tumors, that is, tumor cells are directly killed and cancer-promoting nerve signals are blocked, so that the treatment effect on gastric cancer is remarkably improved. Besides, the double-drug sustained-release preparation is high in safety and good in sustained-release effect, 5-FU and the vagus nerve blocker can be accurately delivered to a tumor area through local injection and in-situ gelation of the temperature-sensitive hydrogel, whole-body exposure of the drug is reduced, local residence time is prolonged, and toxic and side effects are reduced.

A synthetic route to scopolamine and / or atropine. In such context, the present invention identifies a method for preparing 6,7-dehydro atropine, which can be converted into either scopolamine and / or atropine, along with a method for converting a protected pyrrole into a tetrachlorobicylic compound, such as benzyl 3-oxo-8-azabicyclo[3.2.1]oct-6-ene-8-carboxylate.

The present invention belongs to the field of pharmaceutical preparations and specifically relates to an atropine pharmaceutical composition comprising a pharmaceutically acceptable salt of atropine, a sulfonic acid cation exchange resin, and a suspending agent, wherein the suspending agent is selected from one or more of carbomer, povidone, and hydroxyethylcellulose. The atropine pharmaceutical composition of the present invention can significantly reduce the free atropine content in the drug solution, thereby controlling the content of related substances within a low range, ensuring the drug has excellent stability at room temperature and achieving a better drug release effect.

A liquid ophthalmic composition comprising atropine or a pharmaceutically acceptable salt thereof, at least one buffering agent and at least one tonic agent, wherein Atropine or a pharmaceutically acceptable salt thereof is present in the composition in an amount of 0.001% to 0.1% by weight. that at least one buffering agent is present in the composition at a concentration of 0.5 mM to 50 mM, that at least one tonic agent is present in the composition at a concentration of 100 mM to 500 mM, the composition has a pH value of 4.0 to 6.0.

The application provides a method for improving the stability of a low-concentration atropine ophthalmic preparation, characterized by controlling the content of the total impurity ≤0.25% and / or a single impurity content of ≤0.05%, as well as a method for preparing the ophthalmic preparation, an atropine ophthalmic preparation prepared therefrom and use thereof in the manufacture of a medicament for preventing and / or treating vision defects.

The present invention provides an aqueous pharmaceutical composition for the treatment of myopia, prevention of myopia and / or suppression of myopia, comprising atropine or a salt thereof in a concentration of 0.025% (w / v), wherein the aqueous pharmaceutical composition is administered to a myopic patient aged 12 to 15 years.

Gel, ointment, lotion, or cream formulations containing an active pharmaceutical ingredient including a tropanil portion are provided herein. The gel, lotion, or cream formulations may contain at least one low molecular weight (LMW) compound or a pharmaceutically acceptable salt thereof. Also provided herein are gel, ointment, lotion, or cream formulations containing active pharmaceutical ingredients such as atropine, pilocarpine, physostigmine, or travoprost.

The present disclosure is directed, in part, to aqueous pharmaceutical solutions comprising benzyl atropine or a pharmaceutically acceptable salt or prodrug thereof, at least one buffer, at least one tonicity agent, and at least one solubilizing agent, processes of preparing an aqueous solution comprising benzyl atropine, the products of such processes, and methods of preventing myopia, treating myopia, reducing myopia progression, or preventing myopia progression in a subject in need thereof, by administering to the eye of the subject a therapeutically effective amount of such an aqueous pharmaceutical solution.

Ophthalmically-acceptable formulations of atropine and other muscarinic acetylcholine receptor antagonists are provided that can be heat-sterilized without significant degradation of the muscarinic acetylcholine receptor antagonist. The formulations are less acidic than prior muscarinic acetylcholine receptor antagonist ophthalmic formulations, making them more comfortable when administered to the eye.

The application belongs to the field of medicine, and provides atropine salt, a preparation method thereof, a pharmaceutical composition and application. The atropine salt derivative prepared in the application has high activity in the preparation of eye drugs, and has high stability. The compound has good mydriatic effect. The atropine salt derivative prepared in the application has high solubility and stability, and has significant advantages in the preparation of eye drugs and application.

Compositions for therapy of a diabetic symmetrical polyneuropathy a subject in need thereof, the compositions comprising: an effective amount of a muscarinic acetylcholine receptor antagonist exemplified by pirenzepine, telenzepine, atropine, or derivatives thereof or salts thereof or analogs thereof or derivatives thereof, and a pharmacologically acceptable carrier. The composition may be injectable or alternatively, may be applied topically or alternatively, may be delivered orally. A suitable topical composition may comprise a lotion, a cream, a gel, or a viscous fluid. The muscarinic acetylcholine receptor antagonist may be a muscarinic acetylcholine receptor antagonist salt or a muscarinic acetylcholine receptor antagonist derivative or a muscarinic acetylcholine receptor antagonist analog.

The invention provides a construction method and application of a chronic epilepsy co-disease depression mouse model. The method comprises the following steps: firstly, sequentially carrying out operations of intraperitoneal injection of a lithium chloride solution, intraperitoneal injection of an atropine solution and intraperitoneal injection of a pirolocarb solution on mice in an experimental group to induce generation of the epileptic status; recording the epileptic seizure behavior of the mice in the experimental group, and evaluating the epileptic seizure grade of the mice in the experimental group by referring to a Racine standard to obtain a lithium chloride-pirocapene induced chronic epilepsy mouse model; evaluating the mouse depression-like behavior degree by combining a depression-like behavior experiment, screening the lithium chloride-pirocapene induced chronic epilepsy mouse model so as to determine a modeling standard and a modeling time point of the chronic epilepsy co-disease depression mouse model, and obtaining a chronic epilepsy co-disease depression mouse and a chronic epilepsy non-depression mouse; and performing depression-like behavioral comparison on the chronic epilepsy co-disease depression mouse and the chronic epilepsy non-depression mouse to obtain the chronic epilepsy co-disease depression mouse model.

Provided herein are gels, ointments, lotions, or cream formulations comprising an active pharmaceutical ingredient comprising a tropane moiety. The gel, lotion, or cream formulation may comprise at least one low molecular weight (LMW) compound, or a pharmaceutically acceptable salt thereof. Also provided herein are gel, ointment, lotion, or cream formulations comprising an active agent, such as atropine, pilocarpine, hyacinth bean alkali, or travoprost.